

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/756,283	01/09/2001	Yuti Chernajovsky	0623.1000000/LLB/PAJ	5963	
26111 7	7590 09/23/2003				
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			EXAMINER		
			ANDRES, JANET L		
Ž			ART UNIT	PAPER NUMBER	
			1646		
			DATE MAILED: 09/23/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

	· · · · · · · · · · · · · · · · · · ·	Application	No.	Applicant(s)				
Office Action Summary				CHERNAJOVSKY ET AL.				
		09/756,283						
		Examiner	_	Art Unit				
	The MAILING DATE of this communication app	Janet L. Andr		1646 orrespondence address				
Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)⊠								
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ Thi	is action is no	n-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is √								
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>								
,	4)⊠ Claim(s) <u>27 and 30-52</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) <u>34-50</u> is/are allowed.								
	6)⊠ Claim(s) <u>27,30-33 and 51</u> is/are rejected.							
·	7) Claim(s) <u>52</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.								
Application Papers								
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
,	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) 6)	Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)				

Application/Control Number: 09/756,283

Art Unit: 1646

#### RESPONSE TO AMENDMENT

1. Applicant's amendment filed is acknowledged. Claims 27 and 30-52 are pending and under examination in this application. Upon further consideration, the finality of the previous office action is withdrawn. It is noted that a Notice of Appeal and Appeal Brief have been filed. Applicant can request a refund for the associated fees or leave it as credit for future appeals. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

### Claim Rejections Withdrawn

- 2. The rejection of claims 27 and 30-33 under 35 U.S.C. 112, first paragraph, as lacking enablement commensurate in scope with the claims is withdrawn in response to Applicant's amendment.
- 3. The rejection of claims 27 and 30-33 under 35 U.S.C. 103(a) is withdrawn in response to Applicant's amendment.

## New Grounds of Rejection

4. Claims 27, 30-33, and 51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

These claims are drawn to methods of treatment involving interleukins. Unlike the interferons, interleukins are a structurally and functionally diverse family. Not all of the members of this family are anti-inflammatory; as was discussed previously, interleukin-1 is pro-

Application/Control Number: 09/756,283

Art Unit: 1646

inflammatory. Similarly, interleukin-18, which is also known as interferon  $\gamma$  inducing factor, would be expected to have pro-inflammatory effects. Applicant has provided no characteristics by which one of skill in the art could identify anti-inflammatory interleukins. While the art identifies several, it also fails to describe any characteristics that would identify a genus of such molecules. Thus anti-inflammatory interleukins are not described so that one of skill in the art would comprehend that Applicant was in possession of the genus, and of methods of using the genus.

## Allowable Subject Matter

5. Claim 52 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

CLAIMS 27, 30-33, AND 51 ARE REJECTED. CLAIM 52 IS OBJECTED TO. CLAIMS 34-50 ARE ALLOWED.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet Andres, Ph.D., whose telephone number is (703) 305-0557. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564. The fax phone number for this group is (703) 872-9306 or (703) 872-9307 for after final communications.

Page 4

Application/Control Number: 09/756,283

Art Unit: 1646

Communications via internet mail regarding this application, other than those under U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet email communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Janet Andres, Ph.D. September 17, 2003

YVONNE EYLER, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600